NCT05857969View on ClinicalTrials.gov

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

PHASE1RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

February 22, 2028

Study Completion Date

December 31, 2028

Conditions
Recurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Large Cell LymphomaRefractory Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Hodgkin LymphomaRefractory Childhood Malignant Germ Cell NeoplasmRecurrent Childhood Brain TumorRecurrent Childhood Brainstem GliomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood EpendymomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood GliosarcomaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Childhood Malignant Solid NeoplasmRecurrent Childhood Malignant Solid NeoplasmRecurrent Childhood Malignant NeoplasmRefractory Childhood Malignant Neoplasm
Interventions
DEVICE

Functional Precision Medicine

Ex Vivo Drug Sensitivity Testing + Genomic Tumor Profiling

Trial Locations (1)

33155

RECRUITING

Nicklaus Children's Hospital, Miami

All Listed Sponsors
collaborator

Nicklaus Children's Hospital f/k/a Miami Children's Hospital

OTHER

collaborator

First Ascent Biomedical Inc.

INDUSTRY

collaborator

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

lead

Florida International University

OTHER